Volume 7 Issue 3
May  2016
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-9081.2016.03.012
  • Received Date: 2015-12-17
  • Publish Date: 2016-05-30
  • loading
  • [1] Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update[J]. Expert Rev Clin Immunol, 2010, 6: 643-657. doi:  10.1586/eci.10.35
    [2] Protic M, Seibold F, Schoepfer A, et al. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients[J]. J Crohns Colitis, 2014, 8: 1427-1437. doi:  10.1016/j.crohns.2014.05.004
    [3] Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis[J]. Expert Rev Clin Pharmacol, 2012, 5: 113-123. doi:  10.1586/ecp.12.2
    [4] Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer[J]. Nat Rev Drug Discov, 2006, 5: 219-234. doi:  10.1038/nrd1984
    [5] Potter JM, Mcwhinney BC, Sampson L, et al. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population[J]. Ther Drug Monit, 2004, 26: 408-414. doi:  10.1097/00007691-200408000-00011
    [6] Moon W, Loftus EV Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2016, 43: 863-883. doi:  10.1111/apt.13559
    [7] Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients[J]. Eur J Gastroenterol Hepatol, 2012, 24: 958-964. doi:  10.1097/MEG.0b013e3283545ae3
    [8] Stocco G, Cuzzoni E, De Iudicibus S, et al. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms[J]. World J Gastroenterol, 2015, 21: 3571-3578. doi:  10.3748/wjg.v21.i12.3571
    [9] Biancone L, Onali S, Petruzziello C, et al. Cancer and immunomodulators in inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2015, 21: 674-698. doi:  10.1097/MIB.0000000000000243
    [10] Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases[J]. Pharmacogenomics, 2011, 12: 1449-1463. doi:  10.2217/pgs.11.86
    [11] Jansen G, Van Der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis[J]. Arthritis Rheum, 2004, 50: 2130-2139. doi:  10.1002/art.20375
    [12] Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease[J]. Clin Pharmacokinet, 2001, 40: 723-751. doi:  10.2165/00003088-200140100-00003
    [13] Boyle B, Mackner L, Ross C, et al. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease[J]. J Pediatr Gastroenterol Nutr, 2010, 51: 714-717. doi:  10.1097/MPG.0b013e3181dd861a
    [14] Bamba S, Tsujikawa T, Inatomi O, et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis[J]. J Gastroenterol Hepatol, 2010, 25: 494-498. doi:  10.1111/j.1440-1746.2009.06119.x
    [15] Huttunen KM, Tani N, Juvonen RO, et al. Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs[J]. Mol Pharm, 2013, 10: 532-537. doi:  10.1021/mp300330v
    [16] Hardy KW, Crocker JF, Mclellan H, et al. Paradoxical cyclosporine A requirements in pediatric renal transplants receiving high-dose steroids[J]. J Clin Pharmacol, 2005, 45: 161-167. doi:  10.1177/0091270004271403
    [17] Smith MA, Marinaki AM, Sanderson JD. Pharmacogenomics in the treatment of inflammatory bowel disease[J]. Pharmacogenomics, 2010, 11: 421-437. doi:  10.2217/pgs.10.4
    [18] Nakamura K, Matsuzawa N, Ohmori S, et al. Clinical evidence of pharmacokinetic changes in thalidomide therapy[J]. Drug Metab Pharmacokinet, 2013, 28: 38-43. doi:  10.2133/dmpk.DMPK-12-RV-089
    [19] Diamanti A, Capriati T, Papadatou B, et al. The clinical implications of thalidomide in inflammatory bowel diseases[J]. Expert Rev Clin Immunol, 2015, 11: 699-708. doi:  10.1586/1744666X.2015.1027687
    [20] Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2015, 21: 1709-1718. doi:  10.1097/MIB.0000000000000380
    [21] Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis[J]. Am J Gastroenterol, 2013, 108: 40-47. doi:  10.1038/ajg.2012.363
    [22] Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease[J]. N Engl J Med, 2010, 362: 1383-1395. doi:  10.1056/NEJMoa0904492
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (132) PDF downloads(6) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint